Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kezar Life Sciences (KZR) Operating Leases (2021 - 2025)

Historic Operating Leases for Kezar Life Sciences (KZR) over the last 5 years, with Q3 2025 value amounting to $3.3 million.

  • Kezar Life Sciences' Operating Leases changed 0.0% to $3.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.3 million, marking a year-over-year change of 0.0%. This contributed to the annual value of $2.3 million for FY2024, which is 6025.29% down from last year.
  • As of Q3 2025, Kezar Life Sciences' Operating Leases stood at $3.3 million, which was down 0.0% from $4.2 million recorded in Q2 2025.
  • Kezar Life Sciences' Operating Leases' 5-year high stood at $8.9 million during Q4 2022, with a 5-year trough of $2.2 million in Q3 2022.
  • For the 5-year period, Kezar Life Sciences' Operating Leases averaged around $4.6 million, with its median value being $4.1 million (2021).
  • As far as peak fluctuations go, Kezar Life Sciences' Operating Leases skyrocketed by 20131.4% in 2023, and later plummeted by 6025.29% in 2024.
  • Over the past 5 years, Kezar Life Sciences' Operating Leases (Quarter) stood at $3.2 million in 2021, then soared by 175.05% to $8.9 million in 2022, then tumbled by 33.99% to $5.9 million in 2023, then tumbled by 60.25% to $2.3 million in 2024, then surged by 40.11% to $3.3 million in 2025.
  • Its Operating Leases stands at $3.3 million for Q3 2025, versus $4.2 million for Q2 2025 and $5.0 million for Q1 2025.